TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 13 2025
0mins
Source: PRnewswire
TC BioPharm's Clinical Trial Results: TC BioPharm announced favorable preliminary results from the ACHIEVE Phase 2B clinical trial for TCB008, showing no drug-related adverse events and evidence of stable disease in patients with relapse or refractory acute myeloid leukemia (AML).
Future Development Plans: The company plans to further investigate how to sustain stable disease and potentially use TCB008 as a bridge to transplant or in combination with other treatments, following the successful conclusion of Cohort A recruitment.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
